Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1.

Clin Exp Immunol. 1999 Feb;115(2):335-41. Unique Identifier : AIDSLINE MED/99132267
Lu Y; Xin KQ; Hamajima K; Tsuji T; Aoki I; Yang J; Sasaki S; Fukushima J; Yoshimura T; Toda S; Okada E; Okuda K; Department of Bacteriology, Yokohama City University School of; Medicine, Yokohama, Japan.

Abstract: CD8+ cell-secreted CC-chemokines, MIP-1alpha, and MIP-beta have recently been identified as factors which suppress HIV. In this study we co-inoculated MIP-1alpha expression plasmid with a DNA vaccine constructed from HIV-1 pCMV160IIIB and pcREV, and evaluated the effect of the adjuvant on HIV-specific immune responses following intramuscular and intranasal immunization. The levels of both cytotoxic T lymphocyte (CTL) activity and DTH showed that HIV-specific cell-mediated immunity (CMI) was significantly enhanced by co-inoculation of the MIP-1alpha expression plasmid with the DNA vaccine compared with inoculation of the DNA vaccine alone. The HIV-specific serum IgG1/IgG2a ratio was significantly lowered when the plasmid was co-inoculated in both intramuscular and intranasal routes, suggesting a strong elicitation of the T helper (Th) 1-type response. When the MIP-1alpha expression plasmid was inoculated intramuscularly with the DNA vaccine, an infiltration of mononuclear cells was observed at the injection site. After intranasal administration, the level of mucosal secretory IgA antibody was markedly enhanced. These findings demonstrate that MIP-1alpha expression plasmid inoculated together with DNA vaccine acts as a strong adjuvant for eliciting Th1-derived immunity.

Keywords: JOURNAL ARTICLE *Adjuvants, Immunologic Animal AIDS Vaccines/GENETICS/*IMMUNOLOGY/PHARMACOLOGY Drug Synergism Drug Therapy, Combination Female Gene Products, rev/GENETICS/IMMUNOLOGY HIV Antibodies/BLOOD HIV Envelope Protein gp160/GENETICS/IMMUNOLOGY HIV Infections/PREVENTION & CONTROL HIV-1/*IMMUNOLOGY Immunity, Cellular Macrophage Inflammatory Protein-1/GENETICS/*IMMUNOLOGY/ PHARMACOLOGY Mice Mice, Inbred BALB C Support, Non-U.S. Gov't T-Lymphocytes, Cytotoxic Vaccines, DNA/*IMMUNOLOGY/PHARMACOLOGY
990530
A9950892

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .